Bystander suppression of type I diabetes by oral administration of glucagon
US6645504B1 · kind B1 · utility
50Cited by
5References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1995 |
| Grant date | Nov 11, 2003 |
| Priority date | — |
| Expiry date | Jun 6, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/543
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are methods for treating or preventing type I diabetes and insulitis by oral administration of the bystander antigen glucagon. The methods involve oral administration of glucagon in an amounts that are effective to treat or prevent type I diabetes or insulitis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.